The efficacy and safety of β-nicotinamide mononucleotide (nmn) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

HIGHLIGHTS

• who: Lin Yi from the CT, USA Yong Loo Lin School of Medicine, National University have published the Article: The efficacy and safety of u03b2-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial, in the Journal: (JOURNAL) of May/25,/2021
• what: The aim was to evaluate blood NAD concentration with dose-dependent regimens. Participants could be removed from the trial at any time for any of the following reasons: participant`s withdrawal of informed consent and withdrawal by his/her . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.